Transforming Outcomes in AL Amyloidosis with Precision Medicine and Targeted Therapies - Episode 1
Exploring the Landscape Surrounding Light Chain Amyloidosis
Heather Landau, MD, initiates a discussion on the landscape of AL amyloidosis, offering insights into the definition and characteristics of this rare disease.
This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.
Landau discusses AL amyloidosis with Sanchorawala and Zonder. Zonder provides an overview of light chain (AL) amyloidosis, a plasma cell dyscrasia related to multiple myeloma. With 5000 to 6000 cases yearly in the United States, AL amyloidosis involves misfolded light chains forming protein deposits with direct cytotoxicity. Despite challenges, the prevalence is rising due to improved survival and early diagnosis efforts. The discussion emphasizes the role of precision medicine and targeted therapies in transforming outcomes for AL amyloidosis.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.